Invesco India Pharma and Healthcare Fund

A Sectoral/Thematic Fund scheme from Invesco Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF205KA1BX5).

NAV ₹10.6000 on 16 November 2026.

Expense ratio

Total expense ratio 3.30% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.50%, brokerage 0.86%, transaction costs 0.05%, statutory levies including GST 1.89%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino

Too little NAV history for the 1, 3, 5, 10-year figures.

Not ranked in its category: it has too little NAV history.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 97.0% of the portfolio.

  1. Apollo Hospitals Enterprise Limited — 9.08%
  2. Divi's Laboratories Limited — 8.74%
  3. Max Healthcare Institute Limited — 8.59%
  4. Sai Life Sciences Limited — 8.49%
  5. Sun Pharmaceutical Industries Limited — 8.31%
  6. Manipal Health Enterprises Limited — 7.97%
  7. Dr. Agarwal's Health Care Limited — 7.93%
  8. Sahajanand Medical Technologies Limited — 7.31%
  9. Global Health Limited — 5.96%
  10. CORONA Remedies Limited — 5.76%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.